Name: Daclatasvir | BMS-790052; EBP 883
Brand: Ambeed
SKU: A358801

NCT02095860	Hepatitis C	Phase 1	Completed	-	United States, Texas ... More >> Healthcare Discoveries, Llc D/B/A Icon Development Solutions San Antonio, Texas, United States, 78209 Less <<
NCT02531269	-		Completed	-	Switzerland ... More >> Local Institution Basel, Switzerland Less <<
NCT03186313	Hepatitis C	Phase 3	Completed	-	Egypt ... More >> Egyptian Liver Hospital Shirbīn, Dakahlia, Egypt, 35681 Less <<
NCT02170727	Hepatitis C Virus	Phase 3	Completed	-	Korea, Republic of ... More >> Local Institution Busan, Korea, Republic of, 602-739 Local Institution Busan, Korea, Republic of, 614-735 Local Institution Gyeonggi-do, Korea, Republic of, 463-707 Local Institution Gyeonggi-Do, Korea, Republic of, 480-717 Local Institution Gyeongsangnam-do, Korea, Republic of, 626-770 Local Institution Inchoen, Korea, Republic of, 405-760 Local Institution Seoul, Korea, Republic of, 120-752 Local Institution Seoul, Korea, Republic of, 135-710 Local Institution Seoul, Korea, Republic of, 138-736 Local Institution Seoul, Korea, Republic of, 156-755 Russian Federation Local Institution Kazan, Russian Federation, 420140 Local Institution Moscow, Russian Federation, 109240 Taiwan Local Institution Kaohsiung, Taiwan, 807 Local Institution Kaohsiung, Taiwan, 833 Local Institution Taichung, Taiwan, 40447 Local Institution Taichung, Taiwan, 40705 Local Institution Tainan, Taiwan, 704 Local Institution Taipei, Taiwan, 100 Local Institution Taipei, Taiwan, 112 Local Institution Taoyuan, Taiwan, 333 Less <<
NCT02045966	Hepatitis C	Phase 1	Completed	-	-
NCT01016912	Hepatitis C Infection	Phase 2	Completed	-	Japan ... More >> Local Institution Hiroshima City, Hiroshima, Japan, 734-0037 Local Institution Sapporo-Shi, Hokkaido, Japan, 060-0033 Local Institution Kawasaki-Shi, Kanagawa, Japan, 2138587 Local Institution Suita-Shi, Osaka, Japan, 5650871 Local Institution Iruma-Gun, Saitama, Japan, 3500495 Local Institution Minato-Ku, Tokyo, Japan, 105-0001 Less <<
NCT01573351	Hepatitis C Virus	Phase 3	Completed	-	-
NCT02727933	-		Recruiting	September 30, 2020	Korea, Republic of ... More >> Local Institution Recruiting Seoul, Korea, Republic of Contact: Site 0001 Less <<
NCT02250001	-		Completed	-	Japan ... More >> Local Institution Chuo-ku, Tokyo, Japan, 104-0033 Less <<
NCT01016912	-		Completed	-	-
NCT02292966	Hepatitis C, Chronic	Phase 4	Withdrawn	June 2016	Australia, New South Wales ... More >> St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Westmead Hospital Westmead, New South Wales, Australia, 2145 Less <<
NCT03500562	-		Recruiting	December 31, 2021	China, Beijing ... More >> Local Institution Recruiting Beijing, Beijing, China, 100054 Contact: Site 0002 Less <<
NCT01741545	Hepatitis C Virus	Phase 3	Completed	-	-
NCT00983957	-		Completed	-	-
NCT02161939	-		-	-	-
NCT00983957	Chronic Hepatitis C	Phase 1	Completed	-	United States, Arizona ... More >> MDS Pharma Services (US), Inc Tempe, Arizona, United States, 85283 United States, Texas Covance Clinical Research Unit, Inc. Austin, Texas, United States, 78752 Canada, Quebec Local Institution St. Laurent, Quebec, Canada, H4R2N6 Less <<
NCT02175966	Hepatitis C	Phase 2	Completed	-	United States, California ... More >> Inland Empire Liver Foundation Rialto, California, United States, 92377 United States, Illinois Northwestern University Feinberg School Of Medicine Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Health - University Hospital Indianapolis, Indiana, United States, 46202 United States, Maryland Johns Hopkins University Lutherville, Maryland, United States, 21093 United States, Texas Texas Liver Institute San Antonio, Texas, United States, 78215 Less <<
NCT00874770	Hepatitis C Infection	Phase 2	Completed	-	United States, Alabama ... More >> Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States, 36116 United States, Colorado University Of Colorado Denver & Hospital Aurora, Colorado, United States, 80045 United States, Connecticut Yale University School Of Medicine New Haven, Connecticut, United States, 06520 United States, Maryland Mercy Medical Center Baltimore, Maryland, United States, 21202 United States, Massachusetts Llc Dba The Research Institute Springfield, Massachusetts, United States, 01107 United States, New York Veterans Affairs Medical Center Bronx, New York, United States, 10468 United States, North Carolina Carolinas Center For Liver Disease Statesville, North Carolina, United States, 28677 United States, Oklahoma Options Health Research, Llc Tulsa, Oklahoma, United States, 74104 Healthcare Research Consultants Tulsa, Oklahoma, United States, 74135 United States, Texas North Texas Research Institute Arlington, Texas, United States, 76012 United States, Virginia Metropolitan Research Fairfax, Virginia, United States, 22031 France Local Institution Creteil, France, 94010 Local Institution Paris Cedex 14, France, 75679 Local Institution Vandoeuvre Les Nancy, France, 54511 Less <<
NCT00874770	-		Completed	-	-
NCT01359644	Chronic Hepatitis C	Phase 2	Completed	-	United States, California ... More >> Southern California Liver Centers Coronado, California, United States, 92118 Research And Education, Inc. San Diego, California, United States, 92105 United States, Colorado University Of Colorado Denver & Hospital Aurora, Colorado, United States, 80045 United States, Florida University Of Florida Hepatology Gainesville, Florida, United States, 32610 Orlando Immunology Center Orlando, Florida, United States, 32803 Miami Research Associates South Miami, Florida, United States, 33143 United States, Maryland Mercy Medical Center Baltimore, Maryland, United States, 21202 Johns Hopkins University Lutherville, Maryland, United States, 21093 United States, Michigan University Of Michigan Health System Ann Arbor, Michigan, United States, 48109 United States, New York Bronx Va Medical Center 3c Sub-J Bronx, New York, United States, 10468 Weill Cornell Medical College New York, New York, United States, 10021 United States, Oklahoma Options Health Research, Llc Tulsa, Oklahoma, United States, 74104 Healthcare Research Consultants Tulsa, Oklahoma, United States, 74135 United States, Pennsylvania University Of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas Alamo Medical Research San Antonio, Texas, United States, 78215 United States, Virginia Metropolitan Research Annandale, Virginia, United States, 22003 United States, Wisconsin Dean Clinic Madison, Wisconsin, United States, 53715 Puerto Rico Local Institution San Juan, Puerto Rico, 00927 Less <<
NCT00859053	Hepatic Insufficiency	PHASE1	COMPLETED	2025-09-09	Advanced Clinical Research Ins... More >>titute, Anaheim, California, 92801, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT01448044	Hepatitis C	Phase 3	Completed	-	United States, California ... More >> Scti Research Foundation San Clemente, California, United States, 92673 United States, Massachusetts Umass Memorial Medical Center Worcester, Massachusetts, United States, 01655 United States, Rhode Island University Gastroenterology Providence, Rhode Island, United States, 02905 United States, Virginia Metropolitan Research Annandale, Virginia, United States, 22003 France Local Institution Bondy Cedex, France, 93143 Local Institution Creteil, France, 94000 Local Institution La Roche-Sur-Yon Cedex 9, France, 85925 Local Institution Marseille Cedex 08, France, 13285 Local Institution Nice Cedex 03, France, 06202 Local Institution Orleans Cedex 2, France, 45067 Local Institution Paris, France, 75013 Local Institution Paris, France, 75475 Local Institution Strasbourg Cedex, France, 67091 Local Institution Toulouse Cedex 09, France, 31059 Local Institution Villejuif, France, 94804 Greece Local Institution Thesaloniki, Greece, 54639 Italy Local Institution Roma, Italy, 00149 Local Institution Torino, Italy, 10126 Puerto Rico Local Institution San Juan, Puerto Rico, 00927 Spain Local Institution A Coruna, Spain, 15706 Local Institution Barcelona, Spain, 08003 Local Institution Barcelona, Spain, 08035 Local Institution Madrid, Spain, 28046 United Kingdom Local Institution London, Greater London, United Kingdom, SE5 9RS Local Institution London, Greater London, United Kingdom, SW17 0QT Local Institution London, Greater London, United Kingdom, W2 1NY Less <<
NCT01359644	-		Completed	-	-
NCT02103569	Hepatitis C	Phase 1	Completed	-	-
NCT00859053	Hepatic Insufficiency	PHASE1	COMPLETED	2025-09-09	Advanced Clinical Research Ins... More >>titute, Anaheim, California, 92801, United States\|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT01795911	Hepatitis C	Phase 2	Completed	-	United States, Texas ... More >> Alamo Medical Research San Antonio, Texas, United States, 78215 Less <<
NCT01497834	Hepatitis C	Phase 3	Completed	-	Japan ... More >> Local Institution Nagoya-shi, Aichi, Japan, 4668560 Local Institution Chiba-shi, Chiba, Japan, 2608677 Local Institution Fukuoka-shi, Fukuoka, Japan, 8108563 Local Institution Kurume, Fukuoka, Japan, 8300011 Local Institution Ogaki-shi, Gifu, Japan, 5038502 Local Institution Hiroshima-shi, Hiroshima, Japan, 7340037 Local Institution Sapporo-Shi, Hokkaido, Japan, 0600033 Local Institution Amagasaki-shi, Hyogo, Japan, 6608511 Local Institution Kanazawa-shi, Ishikawa, Japan, 9208641 Local Institution Takamatsu-shi, Kagawa, Japan, 7608557 Local Institution Kagoshima-shi, Kagoshima, Japan, 8908520 Local Institution Kawasaki-Shi, Kanagawa, Japan, 2138587 Local Institution Sendai-Shi, Miyagi, Japan, 9808574 Local Institution Okayama-shi, Okayama, Japan, 7008558 Local Institution Osaka-sayama-shi, Osaka, Japan, 5898511 Local Institution Osaka-shi, Osaka, Japan, 5458586 Local Institution Suita-shi, Osaka, Japan, 5650871 Local Institution Suita, Osaka, Japan, 5640013 Local Institution Iruma-Gun, Saitama, Japan, 350-0495 Local Institution Bunkyo-Ku, Tokyo, Japan, 1138655 Local Institution Minato-ku, Tokyo, Japan, 1058470 Local Institution Musashino-shi, Tokyo, Japan, 1808610 Local Institution Shinagawa-ku, Tokyo, Japan, 1428666 Local Institution Chuo-shi, Yamanashi, Japan, 4093898 Less <<
NCT01428063	Hepatitis C Virus Infection	Phase 2	Completed	-	-
NCT01448044	-		Completed	-	-
NCT01017575	-		Completed	-	-
NCT01471574	Hepatitis C, Genotype 1	Phase 3	Completed	-	-
NCT01428063	-		Completed	-	-
NCT03181074	-		Recruiting	April 11, 2019	Mexico ... More >> Local Institution Not yet recruiting Benito Juarez, Distrito Federal, Mexico, 03900 Contact: Site 0002 Local Institution Recruiting Mexico, D.f., Distrito Federal, Mexico, 14050 Contact: Site 0001 Less <<
NCT01017575	Hepatitis C Infection	Phase 2	Completed	-	Japan ... More >> Local Institution Chiba-Shi, Chiba, Japan Local Institution Kurume-Shi, Fukuoka, Japan, 8300011 Local Institution Okayama-Shi, Okayama, Japan, 7008558 Local Institution Osaka-Shi, Osaka, Japan, 5438555 Local Institution Osaka-Shi, Osaka, Japan, 545-8586 Local Institution Musashino-Shi, Tokyo, Japan, 180-0023 Less <<
NCT02673489	Hepatitis C	Phase 3	Completed	-	United States, California ... More >> Keck Medical Center Of USC Los Angeles, California, United States, 90033 University Of California, San Francisco San Francisco, California, United States, 94143 United States, Georgia Gastrointestinal Specialists of Georgia, PC Marietta, Georgia, United States, 30060 United States, Illinois Ruth Rothstein Core Center Chicago, Illinois, United States, 60612 United States, Maryland Digestive Disease Associates, PA Catonsville, Maryland, United States, 21228 United States, Pennsylvania Northeast Clinical Research Center Bethlehem, Pennsylvania, United States, 18017 United States, Rhode Island University Gastroenterology Providence, Rhode Island, United States, 02905 United States, Texas Texas Clinical Research Institute Arlington, Texas, United States, 76012 Methodist Transplant Physicians Dallas, Texas, United States, 75203 The Texas Liver Institute San Antonio, Texas, United States, 78215 United States, Virginia Inova Fairfax Hospital Falls Church, Virginia, United States, 22042 Bon Secours St. Mary's Hospital of Richmond, Inc Richmond, Virginia, United States, 23226 Canada, Alberta Local Institution Calgary, Alberta, Canada, T2N 4Z6 Local Institution Edmonton, Alberta, Canada, T6G 2P4 Canada, British Columbia Local Institution Vancouver, British Columbia, Canada, V6Z 2K5 Local Institution Victoria, British Columbia, Canada, V8V 3P9 Canada, Ontario Local Institution Toronto, Ontario, Canada, M5G 2C4 Canada, Quebec Local Institution Montreal, Quebec, Canada, H3T 1E2 Canada, Saskatchewan Local Institution Regina, Saskatchewan, Canada, S4O 0W5 Less <<
NCT02368522	-		Completed	-	Germany ... More >> Local Institution Hamburg, Germany, 20099 Less <<
NCT02673489	-		Completed	-	-
NCT01629732	Hepatitis C Virus	Phase 2	Withdrawn	June 2014	United States, Florida ... More >> Local Institution Orlando, Florida, United States, 32804 Less <<
NCT01125189	Hepatitis C Virus	Phase 2	Completed	-	-
NCT02762448	-		Withdrawn(no patient enrollmen... More >>t) Less <<	-	-
NCT02639585	Hepatitis C, Chronic	Phase 4	Unknown	June 2017	Korea, Republic of ... More >> Pusan National University Hospital Recruiting Busan, Korea, Republic of, 49241 Contact: Won Lim, M.S. +82-51-240-7869 ezmagic@pusan.ac.kr Pusan National University Yangsan Hospital Recruiting Yangsan, Korea, Republic of, 50612 Contact: Young Mi Hong, M.S. 82-55-360-1570 00gurum@hanmail.net Less <<
NCT01471574	-		Completed	-	-
NCT01425970	Hepatitis C	Phase 2	Terminated(Termination of stud... More >>y was due to safety reasons) Less <<	-	United States, California ... More >> Acri Phase One Anaheim, California, United States, 92801 Scripps Health Dba Scripps Clinical Research Services La Jolla, California, United States, 92037 Quest Clinical Research San Francisco, California, United States, 94115 United States, Missouri Kansas City Cancer Centers, Llc. Kansas City, Missouri, United States, 64111 United States, Oklahoma Options Health Research, Llc Tulsa, Oklahoma, United States, 74104 United States, Texas Alamo Medical Research San Antonio, Texas, United States, 78215 Less <<
NCT00546715	-		Completed	-	-
NCT01389323	Hepatitis C	Phase 3	Completed	-	-
NCT00546715	Chronic Hepatitis C	Phase 1 Phase 2	Completed	-	United States, California ... More >> Advanced Clinical Research Institute Anaheim, California, United States, 92801 United States, Florida Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Maryland Parexel International Corporation Baltimore, Maryland, United States, 21225 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New Jersey Bristol-Myers Squibb Clinical Pharmacology Unit Hamilton, New Jersey, United States, 08690 United States, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 United States, Virginia University Of Virginia Digestive Health Center Of Excellence Charlottesville, Virginia, United States, 22908 Less <<
NCT01125189	-		Completed	-	-
NCT01389323	-		Completed	-	-
NCT01938625	Hepatitis C, Chronic	Phase 2	Completed	-	Germany ... More >> Essen, Germany Hamburg, Germany Poland Warszawa, Poland Spain Barcelona, Spain Madrid, Spain Valencia, Spain Less <<
NCT01938625	-		Completed	-	-
NCT03549832	HCV Coinfection	Not Applicable	Recruiting	January 2019	Egypt ... More >> Assiut University Hopsital Recruiting Assiut, Egypt, 71515 Contact: Mohamed A Mekky, MD Less <<
NCT01866930	Chronic Hepatitis C Infection	Phase 3	Completed	-	-
NCT01616524	Hepatitis C Virus (HCV)	Phase 3	Completed	-	-
NCT01718158	Hepatitis C	Phase 3	Completed	-	-
NCT02323594	Hepatitis C Infection	Phase 1	Completed	-	-
NCT01492426	Hepatitis C	Phase 3	Completed	-	-
NCT00663208	Chronic Hepatitis C	Phase 2	Completed	-	United States, California ... More >> Advanced Clinical Res Inst Anaheim, California, United States, 92801 West Coast Clinical Trials, Llc Cypress, California, United States, 90630 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06510 United States, Florida Elite Research Institute Miami, Florida, United States, 33169 Orlando Clinical Research Center Orlando, Florida, United States, 32809 United States, Maryland Parexel International Corporation Baltimore, Maryland, United States, 21225 United States, Texas Alamo Medical Research San Antonio, Texas, United States, 78215 Puerto Rico Local Institution Santurce, Puerto Rico, 00909 Less <<
NCT03208322	-		Not yet recruiting	October 31, 2019	Mexico ... More >> Local Institution Not yet recruiting Df, Distrito Federal, Mexico, 10700 Contact: Site 0002 Local Institution Not yet recruiting Magdalena De Las Salinas, Distrito Federal, Mexico, 07760 Contact: Site 0001 Less <<
NCT01718145	Hepatitis C Virus Infection	Phase 3	Completed	-	Japan ... More >> Local Institution Nagoya-shi, Aichi, Japan, 4668560 Local Institution Toyoake Shi, Aichi, Japan, 4701192 Local Institution Chiba-shi, Chiba, Japan, 2608677 Local Institution Fukuoka-shi, Fukuoka, Japan, 8108563 Local Institution Kurume, Fukuoka, Japan, 8300011 Local Institution Ogaki-shi, Gifu, Japan, 5038502 Local Institution Takasaki City, Gunma, Japan, 3700829 Local Institution Hiroshima-shi, Hiroshima, Japan, 7340037 Local Institution Obihiro-shi, Hokkaido, Japan, 080-0016 Local Institution Sapporo-shi, Hokkaido, Japan, 0600033 Local Institution Sapporo-shi, Hokkaido, Japan, 0608648 Local Institution Takamatsu-shi, Kagawa, Japan, 760-8557 Local Institution Kagoshima-shi, Kagoshima, Japan, 8908520 Local Institution Kawasaki-shi, Kanagawa, Japan, 2138587 Local Institution Yokohama-shi, Kanagawa, Japan, 2360004 Local Institution Kumamoto-shi, Kumamoto, Japan, 8608556 Local Institution Kyoto-shi, Kyoto, Japan, 6028566 Local Institution Sendai-shi, Miyagi, Japan, 9808574 Local Institution Matsumoto, Nagano, Japan, 3908621 Local Institution Nagasaki-shi, Nagasaki, Japan, 8528501 Local Institution Omura, Nagasaki, Japan, 8568562 Local Institution Kashihara, Nara, Japan, 6348522 Local Institution Yufu, Oita, Japan, 8795593 Local Institution Okayama-shi, Okayama, Japan, 7008558 Local Institution Osaka-sayama-shi, Osaka, Japan, 5898511 Local Institution Osaka-shi, Osaka, Japan, 5438555 Local Institution Osaka-shi, Osaka, Japan, 5458586 Local Institution Suita-shi, Osaka, Japan, 5650871 Local Institution Suita, Osaka, Japan, 5640013 Local Institution Iruma-gun, Saitama, Japan, 3500495 Local Institution Izunokuni, Shizuoka, Japan, 4102295 Local Institution Shimotsuke-shi, Tochigi, Japan, 3290498 Local Institution Bunkyo-ku, Tokyo, Japan, 1138519 Local Institution Bunkyo-ku, Tokyo, Japan, 1138655 Local Institution Minato-ku, Tokyo, Japan, 1058470 Local Institution Musashino-shi, Tokyo, Japan, 1808610 Local Institution Shinagawa-ku, Tokyo, Japan, 1428666 Local Institution Yamagata-shi, Yamagata, Japan, 9909585 Local Institution Chuo-shi, Yamanashi, Japan, 4093898 Local Institution Fukui, Japan, 9188503 Local Institution Fukuoka, Japan, 8140180 Local Institution Fukuoka, Japan, 8158555 Local Institution Gifu, Japan, 5008513 Local Institution Kumamoto, Japan, 8628655 Local Institution Nagoya-shi, Japan, 4678602 Local Institution Nishinomiya-shi, Japan, 6638501 Local Institution Osaka, Japan, 5400006 Local Institution Saitama, Japan, 3380001 Less <<
NCT02473211	Chronic Hepatitis C Infection	Phase 2 Phase 3	Completed	-	China, Beijing ... More >> Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital Beijing, Beijing, China, 100039 China, Hong Kong Humanity and Health GI and Liver Centre Hong Kong, Hong Kong, China, 00852 Less <<
NCT03748745	Drug Interactions	Phase 1	Active, not recruiting	January 19, 2019	China, Jilin ... More >> Phase I Clinical Trial Unit, The First Hospital of Jilin University Changchun, Jilin, China, 130000 Less <<
NCT03080415	Hepatitis C Genotype 4	Phase 3	Completed	-	Egypt ... More >> Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research Nasr City, Cairo, Egypt Less <<
NCT02104843	Hepatitis C	Phase 1	Completed	-	-
NCT01492426	-		Completed	-	-
NCT01725542	HCV-HIV Co-Infection	Phase 2	Completed	-	France ... More >> All the Regions of the Country (33 Centers), France Less <<
NCT02349048	Hepatitis C Virus	Phase 2	Completed	-	United States, California ... More >> Bakersfield, California, United States United States, Florida Jacksonville, Florida, United States United States, Maryland Lutherville, Maryland, United States United States, North Carolina Winston Salem, North Carolina, United States United States, Tennessee Knoxville, Tennessee, United States United States, Texas Arlington, Texas, United States San Antonio, Texas, United States Canada, Ontario Toronto, Ontario, Canada Less <<
NCT02097966	-		-	-	-
NCT02349048	-		Completed	-	-
NCT01995266	Hepatitis C	Phase 3	Completed	-	-
NCT02304159	Hepatitis C C... More >>irrhosis Less <<	Phase 4	Active, not recruiting	December 2017	United States, California ... More >> Southern California Research Center Coronado, California, United States, 92118 Less <<
NCT03366610	-		Recruiting	April 30, 2024	China, Beijing ... More >> Local Institution Recruiting Beijing, Beijing, China Contact: Site 0001 Less <<
NCT03205618	-		Completed	-	Saudi Arabia ... More >> Local Institution Doha, Saudi Arabia Local Institution Jeddah, Saudi Arabia, 23325 Local Institution Riyadh-11211, Saudi Arabia, 11211 Less <<
NCT02098616	Hepatitis C	Not Applicable	Completed	-	United States, California ... More >> VA Long Beach Healthcare System Long Beach, California, United States, 90822 Less <<
NCT03572140	-		Not yet recruiting	August 1, 2020	-
NCT00663208	-		Completed	-	-
NCT02565888	Hepatitis C H... More >>IV Less <<	Phase 1	Completed	-	Netherlands ... More >> CRCN, Radboud University Medical Center Nijmegen, Netherlands Less <<
NCT02107365	Hepatitis C Virus Genotype 4 I... More >>nfection Less <<	Phase 2	Completed	-	France ... More >> Hôpital AVICENNE Bobigny, France, 93009 Hôpital Jean Verdier Bondy, France, 93140 Hôpital de Haut Lévêque Bordeaux Pessac, France, 33601 Hôpital Beaujon Clichy, France, 92110 Centre Hospitalier Intercommunal Créteil, France, 94010 Hôpital Henri Mondor Créteil, France, 94010 Hôpital Albert Michallon Grenoble, France, 38043 Hôpital Claude Huriez Lille, France, 59037 Hôpital Dupuytren Limoges, France, 87042 Hôpital de la Croix Rousse Lyon, France, 69317 Fondation Hôpital Saint Joseph Marseille, France, 13285 Hôpital Saint Eloi Montpellier, France, 34295 Hôpital de Brabois Nancy, France, 54511 Hôpital de l'Hôtel Dieu Nantes, France, 44093 Hôpital de l'Archet Nice, France, 06202 Hôpital de La Source Orléans, France Hôpital Saint Antoine Paris, France, 75571 Hôpital Pitié Salpêtrière Paris, France, 75651 Hôpital Cochin Paris, France, 75679 Hôpital Tenon Paris, France, 75970 Hôpital Pontchaillou Rennes, France, 35000 Hôpital Charles Nicolle Rouen, France, 76031 Institut Arnault Tzank Saint Laurent du Var, France, 06721 Hôpital Purpan Toulouse, France, 31059 Hôpital Paul Brousse Villejuif, France, 94804 Less <<
NCT02319031	Hepatitis C	Phase 3	Completed	-	Australia, New South Wales ... More >> Local Institution Darlinghurst, New South Wales, Australia, 2010 Australia, Queensland Local Institution Greenslopes, Queensland, Australia, 4120 Australia, South Australia Local Institution Adelaide, South Australia, Australia, 5000 Australia, Victoria Local Institution Clayton, Victoria, Australia, 3168 Local Institution Fitzroy, Victoria, Australia, 3065 Local Institution Heidelberg, Victoria, Australia, 3084 France Local Institution Creteil Cedex, France, 94010 Local Institution Grenoble Cedex 09, France, 38043 Local Institution Paris Cedex 14, France, 75679 Local Institution Vandoeuvre Les Nancy, France, 54511 Less <<
NCT01797848	Hepatitis C	Phase 3	Withdrawn	November 2016	-
NCT02319031	-		Completed	-	-
NCT01628692	-		Completed	-	-
NCT02123654	Hepatitis C Virus Infection	Phase 3	Completed	-	Japan ... More >> Local Institution Nagoya-shi, Aichi, Japan, 466-8560 Local Institution Nagoya-shi, Aichi, Japan, 4678602 Local Institution Fukuoka-shi, Fukuoka, Japan, 8108563 Local Institution Kurume-shi, Fukuoka, Japan, 8300011 Local Institution Gifu-shi, Gifu, Japan, 5008513 Local Institution Ogaki-shi, Gifu, Japan, 5038502 Local Institution Takasaki, Gunma, Japan, 3700829 Local Institution Hiroshima-Shi, Hiroshima, Japan, 7348551 Local Institution Sapporo-shi, Hokkaido, Japan, 0600033 Local Institution Sapporo-shi, Hokkaido, Japan, 0608648 Local Institution Kobe-shi, Hyogo, Japan, 6500047 Local Institution Kanazawa-shi, Ishikawa, Japan, 9208641 Local Institution Takamatsu-shi, Kagawa, Japan, 7608557 Local Institution Kagoshima-shi, Kagoshima, Japan, 8908520 Local Institution Kawasaki-shi, Kanagawa, Japan, 2138587 Local Institution Yokohama, Kanagawa, Japan, 2320024 Local Institution Kyoto-shi, Kyoto, Japan, 6028566 Local Institution Kashihara, Nara, Japan, 6348522 Local Institution Okayama-shi, Okayama, Japan, 7008558 Local Institution Osaka-shi, Osaka, Japan, 5438555 Local Institution Osaka-shi, Osaka, Japan, 5458586 Local Institution Suita-shi, Osaka, Japan, 5650871 Local Institution Suita, Osaka, Japan, 5640013 Local Institution Iruma-gun, Saitama, Japan, 3500495 Local Institution Bunkyo-ku, Tokyo, Japan, 1138655 Local Institution Minato-ku, Tokyo, Japan, 1058470 Local Institution Musashino-shi, Tokyo, Japan, 1808610 Local Institution Shinjuku-Ku, Tokyo, Japan, 1608582 Local Institution Yamagata-shi, Yamagata, Japan, 9909585 Local Institution Chuo-shi, Yamanashi, Japan, 4093898 Local Institution Fukui, Japan, 9188503 Local Institution Kumamoto, Japan, 8628655 Local Institution Miyazaki, Japan, 8800003 Local Institution Nishinomiya-shi, Japan, 6638501 Local Institution Saga, Japan, 8408571 Less <<
NCT01628692	Hepatitis C Virus	Phase 2	Completed	-	United States, California ... More >> San Francisco General Hospital San Francisco, California, United States, 94110 Kaiser Permanente Med Ctr San Francisco, California, United States, 94118 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Maryland Johns Hopkins University Lutherville, Maryland, United States, 21093 United States, Tennessee Nashville Medical Research Institute Nashville, Tennessee, United States, 37205 United States, Texas Texas Clinical Research Institute, Llc Arlington, Texas, United States, 76012 United States, Virginia Metropolitan Research Fairfax, Virginia, United States, 22031 Argentina Local Institution Buenos Aires, Argentina, 1119 Local Institution Buenos Aires, Argentina, C1181ACH France Local Institution Creteil Cedex, France, 94010 Local Institution Limoges, France, 87042 Local Institution Marseille Cedex 08, France, 13285 Local Institution Paris Cedex 13, France, 75651 Local Institution Paris Cedex 14, France, 75679 Local Institution Pessac, France, 33600 Local Institution Vandoeuvre Les Nancy, France, 54511 Germany Local Institution Berlin, Germany, 10969 Local Institution Frankfurt, Germany, 60590 Local Institution Hamburg, Germany, 20099 Local Institution Koeln, Germany, 50937 Hungary Local Institution Budapest, Hungary, 1097 Local Institution Budapest, Hungary, 1126 Local Institution Gyula, Hungary, 5700 Spain Local Institution Barcelona, Spain, 08035 Local Institution Madrid, Spain, 28046 Local Institution Valencia, Spain, 46010 Less <<
NCT02032875	Hepatitis C	Phase 3	Completed	-	United States, Florida ... More >> University Of Miami Schiff Center For Liver Diseases Miami, Florida, United States, 33136 United States, Michigan University Of Michigan Health System Ann Arbor, Michigan, United States, 48109 United States, Texas Baylor St. Luke'S Medical Center Houston, Texas, United States, 77030 American Research Corporation San Antonio, Texas, United States, 78215 United States, Washington Harborview Medical Center Seattle, Washington, United States, 98104 Less <<
NCT02780362	Healthy	Phase 1	Completed	-	Egypt ... More >> Genuine Research Center GRC Cairo, Egypt, 11757 Less <<
NCT02032875	-		Completed	-	-
NCT03200184	Hepatitis C	Phase 4	Active, not recruiting	May 1, 2018	Iran, Islamic Republic of ... More >> Shariati Hospital Tehran, Iran, Islamic Republic of, 14117 Less <<
NCT02640157	Chronic Hepatitis C ... More >> Hepatitis C Virus Genotype 3 Hepatitis C Virus Less <<	Phase 3	Completed	-	-
NCT02397395	Renal Impairment ... More >> End-stage Renal Disease Less <<	Phase 2	Withdrawn(Trial has been cance... More >>lled due to availability of new therapeutic options for patient population) Less <<	May 2016	France ... More >> Paris, France Toulouse Cedex 9, France Villejuif, France Spain Barcelona, Spain Madrid, Spain Santander, Spain Less <<
NCT02496078	Hepatitis C	Phase 3	Completed	-	-
NCT02640157	-		Completed	-	-
NCT03686722	Diabetes Mellitus, Type 2 ... More >> Hepatitis C Drug Interactions Less <<	Phase 1	Completed	-	Egypt ... More >> Drug research centre Cairo, Egypt Less <<
NCT02580474	Hepatitis C	Phase 4	Completed	-	Korea, Republic of ... More >> Myeong Jun Song Daejeon, Korea, Republic of Less <<
NCT03490097	Chronic Hepatitis c ... More >> Metabolic Syndrome Less <<	Phase 2 Phase 3	Completed	-	Egypt ... More >> Kobri El koba Armed Forces Hospital Cairo, Egypt Less <<
NCT02556086	Hepatitis C	Phase 2	Withdrawn	July 2017	Canada, Alberta ... More >> Local Institution Edmonton, Alberta, Canada, T6G 2B7 Canada, British Columbia Local Institution Vancouver, British Columbia, Canada, V6Z 2C7 Local Institution Victoria, British Columbia, Canada, V8V 3P9 Canada, Ontario Local Institution Ottawa, Ontario, Canada, K1H 8L6 Local Institution Toronto, Ontario, Canada, M5G 2N2 Canada, Quebec Local Institution Montreal, Quebec, Canada, H4A 3J1 Canada, Saskatchewan Local Institution Regina, Saskatchewan, Canada, S4P 0W5 Canada Local Institution Quebec, Canada, G1V 4G2 France Local Institution Marseille, France, 13009 Local Institution Nantes, France, 44093 Local Institution Nice Cedex, France, 06202 Local Institution Paris Cedex 14, France, 75679 Local Institution Paris Cedex 18, France, 75877 Local Institution Paris, France, 75010 Local Institution Paris, France, 75015 Local Institution Paris, France, 75020 Local Institution Pessac, France, 33604 Less <<
NCT03247296	-		Active, not recruiting	November 10, 2017	Egypt ... More >> National Hepatology and Tropical Medicine Research Institute Cairo, Egypt, 11796 Less <<
NCT02262728	Hepatitis C, Chronic	Phase 2	Completed	-	United States, Texas ... More >> San Antonio, Texas, United States Less <<
NCT01842451	Chronic Hepatitis C ... More >> CHC HCV Hepatitis C Less <<	Phase 2	Completed	-	New Zealand ... More >> New Zealand Auckland, New Zealand New Zealand Christchurch, New Zealand Less <<
NCT03646396	HCV Coinfection	Not Applicable	Recruiting	December 2025	Egypt ... More >> Sherief Abd-Elsalam Recruiting Tanta, Egypt Contact: Sherief Abd-elsalam, lecturer 00201000040794 Sherif_tropical@yahoo.com Less <<
NCT02124044	HIV-HCV	Phase 2	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT02124044	-		Completed	-	-
NCT01492504	-		Completed	-	-
NCT02565862	Hepatitis C D... More >>iabetes Mellitus Insulin Resistance Less <<	Phase 1	Completed	-	Netherlands ... More >> CRCN, Radboud University Medical Center Nijmegen, Netherlands Less <<
NCT03485846	Chronic Hepatitis C Genotype 1... More >>b Less <<	Phase 2	Active, not recruiting	December 2018	Russian Federation ... More >> FBIS CSRI of Epidemiology of Federal Service on Customers Moscow, Russian Federation SBEI HPE Moscow State Medical and Dental University n.a. A.I. Evdokimov of Ministry of Health of Russia Moscow, Russian Federation SBHI of Moscow "City Clinical Hospital #24" Moscow, Russian Federation St. Petersburg SBHI Center of Prevention and Fight against AIDS and Infection Diseases Saint Petersburg, Russian Federation Less <<
NCT02596880	Hepatitis C C... More >>irrhosis Less <<	Phase 3	Completed	-	Iran, Islamic Republic of ... More >> Shariati Hospital Tehran, Iran, Islamic Republic of, 14117 Less <<
NCT02309450	Hepatitis C Virus Genotype 4 I... More >>nfection Less <<	Phase 2	Withdrawn(BMS decision)	August 2016	France ... More >> France All the Regions of the Country, France Less <<
NCT02551861	Hepatitis C	Phase 2	Withdrawn	June 2017	Canada, Alberta ... More >> Local Institution Calgary, Alberta, Canada, T2N 4Z6 Local Institution Edmonton, Alberta, Canada, T6G 2S2 Canada, British Columbia Local Institution Vancouver, British Columbia, Canada, V5Z 1H2 Local Institution Vancouver, British Columbia, Canada, V6Z 2K5 Local Institution Victoria, British Columbia, Canada, V8V 3P9 Canada, Ontario Local Institution Toronto, Ontario, Canada, M5G 2C4 France Local Institution Creteil Cedex, France, 94010 Local Institution Limoges, France, 87042 Local Institution Montpellier Cedex 5, France, 34295 Local Institution Paris Cedex 14, France, 75679 Local Institution Pessac, France, 33604 Local Institution Vandoeuvre Les Nancy, France, 54511 Less <<
NCT02675127	Healthy	Phase 1	Completed	-	Egypt ... More >> Genuine Research Center GRC Cairo, Egypt, 11757 Less <<
NCT02032888	Hepatitis C	Phase 3	Completed	-	-
NCT03487848	Hepatitis C C... More >>hronic Hepatitis Less <<	Phase 2	Recruiting	February 28, 2023	Australia, Victoria ... More >> Local Institution Recruiting Melbourne, Victoria, Australia, 3052 Contact: Site 0008 Germany Local Institution Recruiting Wuppertal, Germany, 42283 Contact: Site 0005 Poland Local Institution Recruiting Krakow, Poland, 31-202 Contact: Site 0007 Local Institution Recruiting Lodz, Poland, 91-347 Contact: Site 0006 Spain Local Institution Recruiting Barcelona, Spain, 8950 Contact: Site 0003 Local Institution Recruiting Madrid, Spain, 28046 Contact: Site 0009 Taiwan Local Institution Recruiting Taipei, Taiwan, 100 Contact: Site 0002 Less <<
NCT02262728	-		Completed	-	-
NCT02032888	-		Completed	-	-
NCT02032901	Hepatitis C	Phase 3	Completed	-	-
NCT02756936	Healthy	Phase 1	Completed	-	Egypt ... More >> Genuine Research Center GRC Cairo, Egypt, 11757 Less <<
NCT02624063	Hepatitis C, Chronic	Phase 4	Completed	-	Brazil ... More >> Outpatient Clinic of Viral Hepatitis (NUPAIG) São Paulo, Brazil, 04025-001 Less <<
NCT02032901	-		Completed	-	-
NCT02268864	Hepatitis C, Chronic	Phase 2	Completed	-	Belgium ... More >> Antwerpen, Belgium Brussel, Belgium Gent, Belgium France Creteil, France Lyon, France Montpellier, France Nice N/A, France Paris Cedex 12, France Paris, France Vandoeuvre Les Nancy, France Germany Frankfurt, Germany Hamburg, Germany Hannover, Germany Kiel, Germany Tübingen, Germany Würzburg, Germany Hungary Budapest, Hungary Debrecen, Hungary Spain Badalona, Spain Barcelona, Spain Santander, Spain Valencia, Spain United Kingdom Birmingham, United Kingdom London, United Kingdom Less <<
NCT03369327	Hepatitis C Virus Infection, R... More >>esponse to Therapy of Human Immunodeficiency Virus Less <<	Phase 3	Completed	-	Iran, Islamic Republic of ... More >> Shariati Hospital Tehran, Iran, Islamic Republic of, 14117 Emam Hospital Tehran, Iran, Islamic Republic of Less <<
NCT02268864	-		Completed	-	-
NCT02159352	Hepatitis C	Phase 1	Completed	-	United States, Texas ... More >> Healthcare Discoveries, Llc D/B/A Icon Development Solutions San Antonio, Texas, United States, 78209 Less <<
NCT01830205	Hepatitis C	PHASE1	COMPLETED	2025-06-13	Orlando Clinical Research Cent... More >>er, Orlando, Florida, 32809, United States\|Davita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT03063879	Hepatitis C, Chronic ... More >> Chronic Renal Failure Less <<	Phase 4	Active, not recruiting	February 1, 2019	Iran, Islamic Republic of ... More >> Shariati Hospital Tehran, Iran, Islamic Republic of, 14117 Less <<
NCT03318887	-		Completed	-	France ... More >> Croix-Rousse Hospital, Hospices Civils de Lyon Lyon, France Less <<
NCT03540212	Chronic HCV Infection	Phase 2 Phase 3	Recruiting	July 1, 2019	Egypt ... More >> Pediatric Department, Faculty of Medicine, Ain Shams University Recruiting Cairo, Non-US, Egypt, 11556 Contact: Manal H El-Sayed, MD 00201227461120 mamalhelsayed@yahoo.co.uk Contact: Fatma Soliman E Ebeid, MD 1095569596 ext Ebeid dr.fatma_ebeid@yahoo.com Principal Investigator: Manal H El-Sayed, MD Sub-Investigator: Fatma SE Ebeid, MD Sub-Investigator: Aya M Kamal, MD Sub-Investigator: Mohamed Hassany, MD Sub-Investigator: Mogeb M Saif, MD Sub-Investigator: Samar F Farid Sub-Investigator: Maggie M Abbassi Sub-Investigator: Sara Makkeyah, MD Sub-Investigator: Mary Akhnokh, MD Less <<
NCT01830205	Hepatitis C	PHASE1	COMPLETED	2025-06-13	Orlando Clinical Research Cent... More >>er, Orlando, Florida, 32809, United States\|Davita Clinical Research, Minneapolis, Minnesota, 55404, United States Less <<
NCT03004625	Hepatitis C	Phase 3	Unknown	December 2017	Taiwan ... More >> Kaohsiung Medical Universsity Recruiting Kaohsiung, Taiwan, 807 Contact: Ming-Lung Yu, MD., PhD. 88673121101 ext 7475 fish6069@gmail.com Contact: Chung-Feng Huang, MD., PhD. 88673121101 ext 7475 fengcheerup@gmail.com Less <<
NCT02865369	-		Not yet recruiting	December 2022	Korea, Republic of ... More >> Soonchunhyang University Cheonan Hospital Recruiting Cheonan, Chungcheongnam-do, Korea, Republic of, 31151 Contact: SaeHwan Lee, Professor Principal Investigator: SaeHwan Lee, Professor Soon Chun Hyang University Bucheon Hospital Recruiting Bucheon, Gyeonggi do, Korea, Republic of, 14584 Contact: Sang Gyune Kim, Professor 82-32-621-5079 mcnulty@schmc.ac.kr Principal Investigator: Sang Gyune Kim Korea University Ansan Hospital Recruiting Ansan, Gyeonggi-do, Korea, Republic of, 15355 Contact: Young Kul Jung, Professor Principal Investigator: Young Kul Jung, Professor Inha University Hospital Recruiting Jung-gu, Incheon, Korea, Republic of, 22332 Contact: Jin-Woo Lee, Professor Principal Investigator: Jin-Woo Lee, Professor Gachon University Gil Medical Center Recruiting Incheon, Korea, Republic of, 21565 Contact: Oh Sang Kwon, Professor Principal Investigator: Oh Sang Kwon, Professor Severance hospital Recruiting Seoul, Korea, Republic of, 03722 Contact: Jun Yong Park, Professor Principal Investigator: Jun Yong Park, Professor Soonchunhyang University Hospital Recruiting Seoul, Korea, Republic of, 04401 Contact: Jae Young Jang, Professor Principal Investigator: Jae Young Jang, Professor Hanyang university hospital Recruiting Seoul, Korea, Republic of, 04763 Contact: Dae Won Jun, Professor Principal Investigator: Dae Won Jun, Professor Ewha Womans University Mokdong Hospital Recruiting Seoul, Korea, Republic of, 07985 Contact: Tae Hun Kim, Professor Principal Investigator: Tae Hun Kim, Professor Wonju severance christian hospital Recruiting Wonju, Korea, Republic of, 26426 Contact: Moon young Kim, Professor Principal Investigator: Moon young Kim, Professor Less <<
NCT02159352	-		Completed	-	-

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1009119-64-5
Formula :	C₄₀H₅₀N₈O₆
M.W :	738.88
SMILES Code :	O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4
Synonyms :	BMS-790052; EBP 883
MDL No. :	MFCD17129086
InChI Key :	OVPGYLMBPQNZNE-GJVQWJCYSA-N
Pubchem ID :	66575053

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Huh7 cells	1 nM	10 days	To evaluate the effect of Daclatasvir on HCV replication and assembly/secretion. Results showed that Daclatasvir treatment led to a decline in intracellular HCV RNA, similar to the polymerase inhibitor NM107, but extracellular HCV titers declined more rapidly, indicating its inhibitory effect on viral assembly/secretion.	PMC3593898
primary RDEB dermal fibroblasts	1 μM	48 h	To evaluate the effect of Daclatasvir on TGF-β signaling pathway, results showed that Daclatasvir inhibited the expression of TGF-β pathway targets collagen I, phosphorylated AKT, and phosphorylated SMAD3.	PMC11018630

Humanized-liver mice	HBV/HCV co-infection model	Oral	30 mg/kg	Once a day for 4 weeks	To evaluate the effect of DAA treatment on HBV replication in HBV/HCV-co-infected mice. Results showed that HCV was eliminated after DAA treatment, and HBV replication was upregulated.	PMC6976581
Alb-uPA/Scid mice	HCV genotype 1b or 3 infection model	Oral	10 mg/kg	Once daily for 4 weeks	Evaluate the inhibitory effect and drug resistance of Daclatasvir monotherapy on HCV	PMC7677215
Human hepatocyte chimeric TK-NOG mice	HCV infection model	Oral	30 mg/kg	Once daily for 4 weeks	To assess the origin of HCV NS5A L31V-Y93H double substitutions after treatment failure with daclatasvir and asunaprevir combination therapy	PMC5278351
Mice	RDEB mouse model	Oral (via drinking water)	30 mg/kg	From conception to weaning (28 days)	To evaluate the effect of Daclatasvir on fibrosis and quality of life in RDEB mice, results showed that Daclatasvir significantly improved survival, increased weight and activity, and reduced pruritus-induced hair loss. Additionally, the expression of fibrosis markers phospho-SMAD3 and collagen I was reduced in the skin.	PMC11018630

{[proInfo.proName]}

CAS No.: 1009119-64-5

{[proInfo.proName]}

CAS No.: 1009119-64-5

Alternative Products

Product Details of Daclatasvir

Safety of Daclatasvir

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	1.35mL 0.27mL 0.14mL	6.77mL 1.35mL 0.68mL	13.53mL 2.71mL 1.35mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed